Centrum Medyczne Pratia Katowice

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes3 trials
• COPD2 trials
• Migraine2 trials
• Sjögren's disease2 trials
• Atrial fibrillation1 trial
• Epilepsy1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Lupus (SLE)1 trial
• Osteoarthritis1 trial
• Osteoporosis1 trial
• Psoriasis1 trial

Phase

• Phase 312 trials
• Phase 43 trials
• Phase 2/31 trial

Status

• Completed11 trials
• Active, not recruiting3 trials
• Recruiting2 trials

Lead sponsor

• Pfizer3 trials
• Novo Nordisk A/S2 trials
• Amgen1 trial
• Bristol-Myers Squibb Services Unlimited Company1 trial
• Eli Lilly and Company1 trial
• and 8 more

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Elzbieta Blach (principal investigator)

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Recruiting

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)

  2022-500699-76-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting

Closed trials

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

  NCT05813912· Phase 3· Novo Nordisk A/S· Source

• Completed

  The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the trial around the participant, known as decentralised, and hybrid clinical trials compared to standard clinical trials that take place in hospitals or in research centres, in patients with type 2 diabetes mellitus treated with Toujeo®, a drug to help manage blood sugar levels.

  2022-500449-26-00· Phase 4· University Medical Center Utrecht· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Pfizer· Source

• Completed

  Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

  NCT05248386· Phase 3· Grünenthal GmbH· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Pfizer· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

  NCT05013229· Phase 3· Novo Nordisk A/S· Source

• Completed

  Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

  NCT05087030· Phase 3· Gedeon Richter Plc.· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· SK Life Science, Inc.· Source